News
Duchenne muscular dystrophy families are sharing stories about Elevidys complications on social media. But they aren’t ...
Another patient has died from acute liver failure after receiving Sarepta’s gene therapy for DMD ; After a quiet start to the ...
12h
MarketBeat on MSNSarepta Drops 42% on Fatalities; Markets Eye Solid BiosciencesIn another tragic incident, Sarepta Therapeutics (NASDAQ: SRPT) saw a second death in connection with its Duchenne muscular ...
In this week’s edition of InnovationRx, we look at the dangers of RFK Jr.’s vaccine advisory committee, how Trump’s visa ban ...
Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate.
I am upgrading Dyne Therapeutics stock to a 'Buy' rating due to promising late-stage DM1 and DMD drug candidates and ...
Gilead has won FDA approval for an HIV prevention shot that is administered only once every six months. When will low-income ...
The bank's head of blockchain solutions Philippe Meyer told the DigiAssets conference in London that it started advising on ...
9h
Investor's Business Daily on MSNGilead Sciences Wins Approval For Highly Effective HIV Prevention DrugGilead Sciences won Food and Drug Administration approval Wednesday for a highly effective drug to prevent HIV infection.
The long-short ratio in the perpetual futures market has fallen to 0.9298, indicating bearish sentiment among traders.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results